<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37072474</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma.</ArticleTitle><Pagination><StartPage>6310</StartPage><MedlinePgn>6310</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6310</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-33585-2</ELocationID><Abstract><AbstractText>Epstein-Barr virus (EBV) is a risk factor for diffuse large B-cell lymphoma (DLBCL) and systemic lupus erythematosus (SLE). While prior research has suggested a potential correlation between SLE and DLBCL, the molecular mechanisms remain unclear. The present study aimed to explore the contribution of EBV infection to the pathogenesis of DLBCL in the individuals with SLE using bioinformatics approaches. The Gene Expression Omnibus database was used to compile the gene expression profiles of EBV-infected B cells (GSE49628), SLE (GSE61635), and DLBCL (GSE32018). Altogether, 72 shared common differentially expressed genes (DEGs) were extracted and enrichment analysis of the shared genes showed that p53 signaling pathway was a common feature of the pathophysiology. Six hub genes were selected using protein-protein interaction (PPI) network analysis, including CDK1, KIF23, NEK2, TOP2A, NEIL3 and DEPDC1, which showed preferable diagnostic values for SLE and DLBCL and involved in immune cell infiltration and immune responses regulation. Finally, TF-gene and miRNA-gene regulatory networks and 10 potential drugs molecule were predicted. Our study revealed the potential molecular mechanisms by which EBV infection contribute to the susceptibility of DLBCL in SLE patients for the first time and identified future biomarkers and therapeutic targets for SLE and DLBCL.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qian-Ying</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518003, People's Republic of China. zhuqy37@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C089441">NEK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000072379">NIMA-Related Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C584411">DEPDC1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072379" MajorTopicYN="N">NIMA-Related Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020690" MajorTopicYN="N">GTPase-Activating Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37072474</ArticleId><ArticleId IdType="pmc">PMC10113247</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-33585-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-33585-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Young LS, Yap LF, Murray PG. Epstein-Barr virus: More than 50 years old and still providing surprises. Nat. Rev. Cancer. 2016;16:789&#x2013;802. doi: 10.1038/nrc.2016.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.92</ArticleId><ArticleId IdType="pubmed">27687982</ArticleId></ArticleIdList></Reference><Reference><Citation>Speck P, Haan KM, Longnecker R. Epstein-Barr virus entry into cells. Virology. 2000;277:1&#x2013;5. doi: 10.1006/viro.2000.0624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0624</ArticleId><ArticleId IdType="pubmed">11062029</ArticleId></ArticleIdList></Reference><Reference><Citation>Odumade OA, Hogquist KA, Balfour HH., Jr Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol. Rev. 2011;24:193&#x2013;209. doi: 10.1128/CMR.00044-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00044-10</ArticleId><ArticleId IdType="pmc">PMC3021204</ArticleId><ArticleId IdType="pubmed">21233512</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari V, Bhatt KH, Smith C, Khanna R. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: Challenges and opportunities. Expert. Rev. Vaccines. 2017;16:377&#x2013;390. doi: 10.1080/14760584.2017.1293529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2017.1293529</ArticleId><ArticleId IdType="pubmed">28276306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: An important vaccine target for cancer prevention. Sci. Transl. Med. 2011;3:107. doi: 10.1126/scitranslmed.3002878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002878</ArticleId><ArticleId IdType="pmc">PMC3501269</ArticleId><ArticleId IdType="pubmed">22049067</ArticleId></ArticleIdList></Reference><Reference><Citation>Justiz Vaillant, A. A., Goyal, A. &amp; Varacallo, M. In StatPearls (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">30571026</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S, Long H, Lu Q. Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. Int. Immunopharmacol. 2020;89:107028. doi: 10.1016/j.intimp.2020.107028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107028</ArticleId><ArticleId IdType="pubmed">33039962</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi MY, Fritzler MJ. Autoantibodies in SLE: Prediction and the p value matrix. Lupus. 2019;28:1285&#x2013;1293. doi: 10.1177/0961203319868531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319868531</ArticleId><ArticleId IdType="pubmed">31399014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jog NR, James JA. Epstein barr virus and autoimmune responses in systemic lupus erythematosus. Front. Immunol. 2020;11:623944. doi: 10.3389/fimmu.2020.623944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.623944</ArticleId><ArticleId IdType="pmc">PMC7886683</ArticleId><ArticleId IdType="pubmed">33613559</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front. Med. (Lausanne) 2022;9:849120. doi: 10.3389/fmed.2022.849120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.849120</ArticleId><ArticleId IdType="pmc">PMC8914279</ArticleId><ArticleId IdType="pubmed">35280878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghabeshi S, et al. Evaluation of molecular apoptosis signaling pathways and its correlation with EBV viral load in SLE patients using systems biology approach. Hum. Antibodies. 2022;30:37&#x2013;46. doi: 10.3233/HAB-211505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/HAB-211505</ArticleId><ArticleId IdType="pubmed">34864653</ArticleId></ArticleIdList></Reference><Reference><Citation>Martelli M, et al. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 2013;87:146&#x2013;171. doi: 10.1016/j.critrevonc.2012.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2012.12.009</ArticleId><ArticleId IdType="pubmed">23375551</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: New targets and novel therapies. Blood Cancer J. 2021;11:68. doi: 10.1038/s41408-021-00456-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00456-w</ArticleId><ArticleId IdType="pmc">PMC8021545</ArticleId><ArticleId IdType="pubmed">33820908</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz R, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 2018;378:1396&#x2013;1407. doi: 10.1056/NEJMoa1801445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1801445</ArticleId><ArticleId IdType="pmc">PMC6010183</ArticleId><ArticleId IdType="pubmed">29641966</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabay P. Advances in the pathogenesis of EBV-associated diffuse large B cell lymphoma. Cancers (Basel) 2021;13:2021. doi: 10.3390/cancers13112717.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13112717</ArticleId><ArticleId IdType="pmc">PMC8199155</ArticleId><ArticleId IdType="pubmed">34072731</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, et al. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. PLoS Pathog. 2020;16:e1008590. doi: 10.1371/journal.ppat.1008590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008590</ArticleId><ArticleId IdType="pmc">PMC7316346</ArticleId><ArticleId IdType="pubmed">32542010</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy JA, Dave SS. The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr. Top. Microbiol. Immunol. 2015;390:315&#x2013;337. doi: 10.1007/978-3-319-22822-8_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-22822-8_13</ArticleId><ArticleId IdType="pubmed">26424652</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leuk. Res. 2018;75:45&#x2013;49. doi: 10.1016/j.leukres.2018.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2018.11.004</ArticleId><ArticleId IdType="pubmed">30458319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tessier-Cloutier B, et al. Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: Molecular and clinical factors associated with survival. Lupus Sci. Med. 2019;6:e000324. doi: 10.1136/lupus-2019-000324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000324</ArticleId><ArticleId IdType="pmc">PMC6541753</ArticleId><ArticleId IdType="pubmed">31205728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumber MR, et al. Lupus nephritis associated with CD20+ B-cell NHL. J. Assoc. Phys. India. 2011;59:520&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">21887914</ArticleId></ArticleIdList></Reference><Reference><Citation>Abenavoli L, et al. Aggressive large B-cell lymphoma in a systemic lupus erythematosus patient with chronic active Epstein-Barr virus infection: A case report. Int. J. Immunopathol. Pharmacol. 2011;24:1083&#x2013;1086. doi: 10.1177/039463201102400427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201102400427</ArticleId><ArticleId IdType="pubmed">22230415</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LW, et al. Epstein-Barr-virus-induced one-carbon metabolism drives B cell transformation. Cell Metab. 2019;30:539&#x2013;555. doi: 10.1016/j.cmet.2019.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.06.003</ArticleId><ArticleId IdType="pmc">PMC6720460</ArticleId><ArticleId IdType="pubmed">31257153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Jiao Y, Zhang X. Immunometabolic pathways and its therapeutic implication in autoimmune diseases. Clin. Rev. Allergy Immunol. 2021;60:55&#x2013;67. doi: 10.1007/s12016-020-08821-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-020-08821-6</ArticleId><ArticleId IdType="pubmed">33179144</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraslan Z, Papatzikas G, Cazier JB, Khanim FL, Gunther UL. Targeting asparagine and serine metabolism in germinal centre-derived B cells non-hodgkin lymphomas (B-NHL) Cells. 2021;10:253. doi: 10.3390/cells10102589.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102589</ArticleId><ArticleId IdType="pmc">PMC8533740</ArticleId><ArticleId IdType="pubmed">34685569</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 2002;21:954&#x2013;965. doi: 10.1093/emboj/21.5.954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.5.954</ArticleId><ArticleId IdType="pmc">PMC125896</ArticleId><ArticleId IdType="pubmed">11867523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cone AS, York SB, Meckes DG., Jr Extracellular vesicles in Epstein-Barr virus pathogenesis. Curr. Clin. Microbiol. Rep. 2019;6:121&#x2013;131. doi: 10.1007/s40588-019-00123-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40588-019-00123-6</ArticleId><ArticleId IdType="pmc">PMC7015464</ArticleId><ArticleId IdType="pubmed">32051811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bareke H, et al. Autoimmune responses in oncology: Causes and significance. Int. J. Mol. Sci. 2021;22:8030. doi: 10.3390/ijms22158030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158030</ArticleId><ArticleId IdType="pmc">PMC8347170</ArticleId><ArticleId IdType="pubmed">34360795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, Chen Y, Jia X, Liu Y. The anti-apoptotic role of EBV-LMP1 in lymphoma cells. Cancer Manag. Res. 2020;12:8801&#x2013;8811. doi: 10.2147/CMAR.S260583.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S260583</ArticleId><ArticleId IdType="pmc">PMC7519810</ArticleId><ArticleId IdType="pubmed">33061576</ArticleId></ArticleIdList></Reference><Reference><Citation>Leech M, et al. The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clin. Exp. Immunol. 2008;152:345&#x2013;353. doi: 10.1111/j.1365-2249.2008.03629.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2008.03629.x</ArticleId><ArticleId IdType="pmc">PMC2384110</ArticleId><ArticleId IdType="pubmed">18341615</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuda Y, Okuda M, Bernard CC. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2003;135:29&#x2013;37. doi: 10.1016/s0165-5728(02)00428-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-5728(02)00428-9</ArticleId><ArticleId IdType="pubmed">12576221</ArticleId></ArticleIdList></Reference><Reference><Citation>Herkel J, et al. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J. Autoimmun. 2001;17:63&#x2013;69. doi: 10.1006/jaut.2001.0518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.2001.0518</ArticleId><ArticleId IdType="pubmed">11488638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado JO, Salvador M, Bonatto D. Importance of the trans-sulfuration pathway in cancer prevention and promotion. Mol. Cell Biochem. 2007;301:1&#x2013;12. doi: 10.1007/s11010-006-9389-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-006-9389-y</ArticleId><ArticleId IdType="pubmed">17180248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajesh BV, Lichtensztejn Z, McManus KJ. Sister chromatid cohesion defects are associated with chromosome instability in Hodgkin lymphoma cells. BMC Cancer. 2013;13:391. doi: 10.1186/1471-2407-13-391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-13-391</ArticleId><ArticleId IdType="pmc">PMC3751861</ArticleId><ArticleId IdType="pubmed">23962039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurse P. A long twentieth century of the cell cycle and beyond. Cell. 2000;100:71&#x2013;78. doi: 10.1016/s0092-8674(00)81684-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)81684-0</ArticleId><ArticleId IdType="pubmed">10647932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernasconi M, et al. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases. Int. J. Cancer. 2013;133:2341&#x2013;2350. doi: 10.1002/ijc.28239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28239</ArticleId><ArticleId IdType="pubmed">23640782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagato T, et al. Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Lab. Invest. 2019;99:612&#x2013;624. doi: 10.1038/s41374-018-0182-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-018-0182-9</ArticleId><ArticleId IdType="pubmed">30664711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao XF, Gartenhaus RB. Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin. Ther. Targets. 2009;13:1085&#x2013;1093. doi: 10.1517/14728220903103833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728220903103833</ArticleId><ArticleId IdType="pubmed">19614561</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Gong H, Huang K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci. 2013;104:651&#x2013;656. doi: 10.1111/cas.12138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.12138</ArticleId><ArticleId IdType="pmc">PMC7657121</ArticleId><ArticleId IdType="pubmed">23438337</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, et al. KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry. Med. (Baltim.) 2022;101:e29312. doi: 10.1097/MD.0000000000029312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000029312</ArticleId><ArticleId IdType="pmc">PMC9276187</ArticleId><ArticleId IdType="pubmed">35713434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, et al. NEK2 promotes cell proliferation and glycolysis by regulating PKM2 abundance via phosphorylation in diffuse large B-cell lymphoma. Front. Oncol. 2021;11:677763. doi: 10.3389/fonc.2021.677763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.677763</ArticleId><ArticleId IdType="pmc">PMC8217770</ArticleId><ArticleId IdType="pubmed">34168996</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U, et al. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am. J. Hematol. 2009;84:803&#x2013;808. doi: 10.1002/ajh.21549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21549</ArticleId><ArticleId IdType="pubmed">19844990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer. 2009;9:327&#x2013;337. doi: 10.1038/nrc2608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2608</ArticleId><ArticleId IdType="pmc">PMC2730144</ArticleId><ArticleId IdType="pubmed">19377505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, et al. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2018;32:663&#x2013;674. doi: 10.1038/leu.2017.215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.215</ArticleId><ArticleId IdType="pmc">PMC5829046</ArticleId><ArticleId IdType="pubmed">28690315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Q, et al. Comparative Analysis on abnormal methylome of differentially expressed genes and disease pathways in the immune cells of RA and SLE. Front. Immunol. 2021;12:668007. doi: 10.3389/fimmu.2021.668007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.668007</ArticleId><ArticleId IdType="pmc">PMC8165287</ArticleId><ArticleId IdType="pubmed">34079550</ArticleId></ArticleIdList></Reference><Reference><Citation>Das TK, Sangodkar J, Negre N, Narla G, Cagan RL. Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene. 2013;32:3184&#x2013;3197. doi: 10.1038/onc.2012.326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.326</ArticleId><ArticleId IdType="pmc">PMC3696049</ArticleId><ArticleId IdType="pubmed">22890320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, et al. Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc. Natl. Acad. Sci. USA. 2014;111:421&#x2013;426. doi: 10.1073/pnas.1321704111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1321704111</ArticleId><ArticleId IdType="pmc">PMC3890834</ArticleId><ArticleId IdType="pubmed">24344258</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S, et al. miRNA-192 and -215 activate Wnt/beta-catenin signaling pathway in gastric cancer via APC. J. Cell Physiol. 2020;235:6218&#x2013;6229. doi: 10.1002/jcp.29550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29550</ArticleId><ArticleId IdType="pubmed">32091625</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao JB, Zhu MN, Zhu XL. miRNA-215-5p suppresses the aggressiveness of breast cancer cells by targeting Sox9. FEBS Open Bio. 2019;9:1957&#x2013;1967. doi: 10.1002/2211-5463.12733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12733</ArticleId><ArticleId IdType="pmc">PMC6823282</ArticleId><ArticleId IdType="pubmed">31538724</ArticleId></ArticleIdList></Reference><Reference><Citation>Radwan AF, Shaker OG, El-Boghdady NA, Senousy MA. Association of MALAT1 and PVT1 variants, expression profiles and target miRNA-101 and miRNA-186 with colorectal cancer: Correlation with epithelial-mesenchymal transition. Int. J. Mol. Sci. 2021;22:6147. doi: 10.3390/ijms22116147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116147</ArticleId><ArticleId IdType="pmc">PMC8201273</ArticleId><ArticleId IdType="pubmed">34200314</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556&#x2013;W560. doi: 10.1093/nar/gkz430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz430</ArticleId><ArticleId IdType="pmc">PMC6602440</ArticleId><ArticleId IdType="pubmed">31114875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. J. Transl. Med. 2022;20:615. doi: 10.1186/s12967-022-03807-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03807-8</ArticleId><ArticleId IdType="pmc">PMC9783715</ArticleId><ArticleId IdType="pubmed">36564797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavoni G, Mattei F, Gabriele L. Type I Interferons as stimulators of DC-mediated cross-priming: Impact on anti-tumor response. Front. Immunol. 2013;4:483. doi: 10.3389/fimmu.2013.00483.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00483</ArticleId><ArticleId IdType="pmc">PMC3872318</ArticleId><ArticleId IdType="pubmed">24400008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong TM, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res. 2007;13:4759&#x2013;4768. doi: 10.1158/1078-0432.CCR-07-0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-07-0001</ArticleId><ArticleId IdType="pubmed">17699853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: A checkpoint target with unique implications for cancer immunology and immunotherapy. J. Immunother. Cancer. 2020;8:2. doi: 10.1136/jitc-2020-000967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-000967</ArticleId><ArticleId IdType="pmc">PMC7368550</ArticleId><ArticleId IdType="pubmed">32675311</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin DP, et al. Lucanthone targets lysosomes to perturb glioma proliferation, chemoresistance and stemness, and slows tumor growth in vivo. Front. Oncol. 2022;12:852940. doi: 10.3389/fonc.2022.852940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.852940</ArticleId><ArticleId IdType="pmc">PMC9048484</ArticleId><ArticleId IdType="pubmed">35494072</ArticleId></ArticleIdList></Reference><Reference><Citation>Carew JS, et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J. Biol. Chem. 2011;286:6602&#x2013;6613. doi: 10.1074/jbc.M110.151324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.151324</ArticleId><ArticleId IdType="pmc">PMC3057822</ArticleId><ArticleId IdType="pubmed">21148553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda N, Tsuchida T, Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthrit. Rheum. 1997;40:1703&#x2013;1711. doi: 10.1002/art.1780400921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400921</ArticleId><ArticleId IdType="pubmed">9324026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzarro A, et al. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. J. Clin. Endocrinol. Metab. 1987;64:32&#x2013;36. doi: 10.1210/jcem-64-1-32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-64-1-32</ArticleId><ArticleId IdType="pubmed">3097058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawazoe A, Shitara K. Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Expert Rev. Gastroenterol. Hepatol. 2020;14:65&#x2013;70. doi: 10.1080/17474124.2020.1715209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2020.1715209</ArticleId><ArticleId IdType="pubmed">31920125</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: A review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs. 1982;23:329&#x2013;353. doi: 10.2165/00003495-198223050-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-198223050-00001</ArticleId><ArticleId IdType="pubmed">6284470</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, et al. NCBI GEO: Archive for functional genomics data sets&#x2013;10 years on. Nucleic Acids Res. 2011;39:D1005&#x2013;1010. doi: 10.1093/nar/gkq1184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq1184</ArticleId><ArticleId IdType="pmc">PMC3013736</ArticleId><ArticleId IdType="pubmed">21097893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, et al. Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B-cell immortalization. Genome Res. 2014;24:177&#x2013;184. doi: 10.1101/gr.157743.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.157743.113</ArticleId><ArticleId IdType="pmc">PMC3912409</ArticleId><ArticleId IdType="pubmed">24068705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Abad C, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 2011;118:5517&#x2013;5527. doi: 10.1182/blood-2011-03-344374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-344374</ArticleId><ArticleId IdType="pubmed">21937691</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T, et al. NCBI GEO: Archive for functional genomics data sets&#x2013;update. Nucleic Acids Res. 2013;41:D991&#x2013;995. doi: 10.1093/nar/gks1193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId><ArticleId IdType="pmc">PMC3531084</ArticleId><ArticleId IdType="pubmed">23193258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV, et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90&#x2013;97. doi: 10.1093/nar/gkw377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw377</ArticleId><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ontology C. The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 2021;49:D325&#x2013;D334. doi: 10.1093/nar/gkaa1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1113</ArticleId><ArticleId IdType="pmc">PMC7779012</ArticleId><ArticleId IdType="pubmed">33290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens M, et al. WikiPathways: Connecting communities. Nucleic Acids Res. 2021;49:D613&#x2013;D621. doi: 10.1093/nar/gkaa1024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1024</ArticleId><ArticleId IdType="pmc">PMC7779061</ArticleId><ArticleId IdType="pubmed">33211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassal B, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48:D498&#x2013;D503. doi: 10.1093/nar/gkz1031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1031</ArticleId><ArticleId IdType="pmc">PMC7145712</ArticleId><ArticleId IdType="pubmed">31691815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49:D545&#x2013;D551. doi: 10.1093/nar/gkaa970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa970</ArticleId><ArticleId IdType="pmc">PMC7779016</ArticleId><ArticleId IdType="pubmed">33125081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27&#x2013;30. doi: 10.1093/nar/28.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947&#x2013;1951. doi: 10.1002/pro.3715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3715</ArticleId><ArticleId IdType="pmc">PMC6798127</ArticleId><ArticleId IdType="pubmed">31441146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587&#x2013;D592. doi: 10.1093/nar/gkac963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac963</ArticleId><ArticleId IdType="pmc">PMC9825424</ArticleId><ArticleId IdType="pubmed">36300620</ArticleId></ArticleIdList></Reference><Reference><Citation>Darryl N. BioCarta. Biotech. Softw. Internet Rep. 2001;2:117&#x2013;120. doi: 10.1089/152791601750294344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/152791601750294344</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607&#x2013;D613. doi: 10.1093/nar/gky1131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2. doi: 10.1186/1471-2105-4-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-4-2</ArticleId><ArticleId IdType="pmc">PMC149346</ArticleId><ArticleId IdType="pubmed">12525261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin CH, et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014;8(4):S11. doi: 10.1186/1752-0509-8-S4-S11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-0509-8-S4-S11</ArticleId><ArticleId IdType="pmc">PMC4290687</ArticleId><ArticleId IdType="pubmed">25521941</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz M, et al. GeneMANIA update 2018. Nucleic Acids Res. 2018;46:W60&#x2013;W64. doi: 10.1093/nar/gky311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky311</ArticleId><ArticleId IdType="pmc">PMC6030815</ArticleId><ArticleId IdType="pubmed">29912392</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CA, et al. The Encyclopedia of DNA elements (ENCODE): Data portal update. Nucleic Acids Res. 2018;46:D794&#x2013;D801. doi: 10.1093/nar/gkx1081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1081</ArticleId><ArticleId IdType="pmc">PMC5753278</ArticleId><ArticleId IdType="pubmed">29126249</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Benner MJ, Hancock RE. NetworkAnalyst&#x2013;integrative approaches for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014;42:W167&#x2013;174. doi: 10.1093/nar/gku443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku443</ArticleId><ArticleId IdType="pmc">PMC4086107</ArticleId><ArticleId IdType="pubmed">24861621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu SD, et al. miRTarBase: A database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39:D163&#x2013;169. doi: 10.1093/nar/gkq1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq1107</ArticleId><ArticleId IdType="pmc">PMC3013699</ArticleId><ArticleId IdType="pubmed">21071411</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509&#x2013;W514. doi: 10.1093/nar/gkaa407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa407</ArticleId><ArticleId IdType="pmc">PMC7319575</ArticleId><ArticleId IdType="pubmed">32442275</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo M, et al. DSigDB: Drug signatures database for gene set analysis. Bioinformatics. 2015;31:3069&#x2013;3071. doi: 10.1093/bioinformatics/btv313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv313</ArticleId><ArticleId IdType="pmc">PMC4668778</ArticleId><ArticleId IdType="pubmed">25990557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>